Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal International Journal of Health and Pharmaceutical (IJHP)
Wulandari Harahap, Putri
Unknown Affiliation
Nursing Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Adverse Event Of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Treatment In Medan Among Pulmonary Adenocarcinoma: Focus On Non-Hematologic Toxicity Wulandari Harahap, Putri; Putra Tarigan, Setia; Novisari Soeroso, Noni
International Journal of Health and Pharmaceutical (IJHP) Vol. 5 No. 3 (2025): August 2025 (Indonesia - Malaysia)
Publisher : CV. Inara

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51601/ijhp.v5i3.429

Abstract

This study aims to compare the non-hematological toxicities of first and second-generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in pulmonary adenocarcinoma patients with positive EGFR mutations in Medan. Utilizing a retrospective cross-sectional design, data were collected from medical records of 66 patients at three hospitals between January 2017 and December 2022. The study population included all patients meeting the specific criteria, and a total sampling technique was used. The collected data on demographics and non-hematological side effects were analyzed using the SPSS program, with the Kolmogorov-Smirnov and chi-square tests. The results indicate that second-generation TKIs exhibit lower non-hematological toxicities, specifically for skin rash, stomatitis, and diarrhea, compared to first-generation TKIs. However, a significant association was found between second-generation TKIs and a higher incidence of paronychia. All observed side effects were low-grade. The study's limitations include its retrospective nature and focus on non-hematological toxicities. Future research should investigate the toxicity profiles of second-generation TKIs further, including hematological side effects.
Co-Authors Novisari Soeroso, Noni Putra Tarigan, Setia